Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 5/2019

01-05-2019 | Original Article

Surgical Delay Is Associated with Improved Survival in Hepatocellular Carcinoma: Results of the National Cancer Database

Authors: Kerui Xu, Shinobu Watanabe-Galloway, Fedja A. Rochling, Paraskevi A. Farazi, K. M. Monirul Islam, Hongmei Wang, Jiangtao Luo

Published in: Journal of Gastrointestinal Surgery | Issue 5/2019

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the fastest growing causes of cancer-related death in the USA. Studies that investigated the impact of HCC therapeutic delays are limited to single centers, and no large-scale database research has been conducted. This study investigated the association of surgical delay and survival in HCC patients.

Methods

Patients underwent local tumor destruction and hepatic resection for stages I–III HCC were identified from the 2004 to 2013 Commission on Cancer’s National Cancer Database. Surgical delay was defined as > 60 days from the date of diagnosis to surgery. Generalized linear-mixed model assessed the demographic and clinical factors associated with delay, and frailty Cox proportional hazard analysis examined the prognostic factors for overall survival.

Results

A total of 12,102 HCC patients met the eligibility criteria. Median wait time to surgery was 50 days (interquartile range, 29–86), and 4987 patients (41.2%) had surgical delay. Delayed patients demonstrated better 5-year survival for local tumor destruction (29.1 vs. 27.6%; P = .001) and resection (44.1 vs. 41.0%; P = .007). Risk-adjusted model indicated that delayed patients had a 7% decreased risk of death (HR, 0.93; 95% CI, 0.87–0.99; P = .027). Similar findings were also observed using other wait time cutoffs at 50, 70, 80, 90, and 100 days.

Conclusions

A plausible explanation of this finding may be case prioritization, in which patients with more severe and advanced disease who were at higher risk of death received earlier surgery, while patients with less-aggressive tumors were operated on later and received more comprehensive preoperative evaluation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67(4):273–289.CrossRefPubMed Islami F, Miller KD, Siegel RL, Fedewa SA, Ward EM, Jemal A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67(4):273–289.CrossRefPubMed
3.
go back to reference U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2017. Available at: www.cdc.gov/uscs. Accessed 22 December 2017. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2017. Available at: www.​cdc.​gov/​uscs. Accessed 22 December 2017.
5.
go back to reference McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol. 2011;54(5):1055–1062.CrossRefPubMed McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol. 2011;54(5):1055–1062.CrossRefPubMed
6.
go back to reference Bhardwaj N, Perera MTPR, Silva MA. Current treatment approaches to HCC with a special consideration to transplantation. J Transplant. 2016;2016:7926264.CrossRefPubMedPubMedCentral Bhardwaj N, Perera MTPR, Silva MA. Current treatment approaches to HCC with a special consideration to transplantation. J Transplant. 2016;2016:7926264.CrossRefPubMedPubMedCentral
7.
go back to reference Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnu L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F, Italian Liver Cancer (ITA.LI.CA) Group Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190.CrossRefPubMed Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnu L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F, Italian Liver Cancer (ITA.LI.CA) Group Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190.CrossRefPubMed
8.
go back to reference Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11(5):472–477.CrossRefPubMed Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11(5):472–477.CrossRefPubMed
9.
go back to reference Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2013;11(9):1101–1108.CrossRefPubMedPubMedCentral Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2013;11(9):1101–1108.CrossRefPubMedPubMedCentral
10.
go back to reference Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, Hamilton W, Hendry A, Hendry M, Lewis R, Macleod U, Mitchell ED, Pickett M, Rai T, Shaw K, Stuart N, Tørring ML, Wilkinson C, Williams B, Williams N, Emery J. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112 Suppl 1:S92-S107.CrossRefPubMedPubMedCentral Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, Hamilton W, Hendry A, Hendry M, Lewis R, Macleod U, Mitchell ED, Pickett M, Rai T, Shaw K, Stuart N, Tørring ML, Wilkinson C, Williams B, Williams N, Emery J. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112 Suppl 1:S92-S107.CrossRefPubMedPubMedCentral
11.
go back to reference Huo TI, Huang YH, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scan J Gastroenterol. 2007;42(4):485–492.CrossRef Huo TI, Huang YH, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scan J Gastroenterol. 2007;42(4):485–492.CrossRef
12.
go back to reference Chen WT, Fernandes ML, Lin CC, Lin SM. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. J Surg Oncol. 2011;103(2):133–139.CrossRefPubMed Chen WT, Fernandes ML, Lin CC, Lin SM. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. J Surg Oncol. 2011;103(2):133–139.CrossRefPubMed
13.
go back to reference Brahmania M, Ahmed O, Kelley M, Wong D, Kowgier M, Khalili K, Beercroft R, Renner EL, Shah H, Feld J, Janssen HLA, Sherman M. Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma. Ann Hepatol. 2017;16(5):765–771.CrossRefPubMed Brahmania M, Ahmed O, Kelley M, Wong D, Kowgier M, Khalili K, Beercroft R, Renner EL, Shah H, Feld J, Janssen HLA, Sherman M. Wait time for curative intent radio frequency ablation is associated with increased mortality in patients with early stage hepatocellular carcinoma. Ann Hepatol. 2017;16(5):765–771.CrossRefPubMed
14.
go back to reference Croome KP, Chudzinski R, Hanto DW. Increasing time delay from presentation until surgical referral for hepatobiliary malignancies. HPB (Oxford). 2010;12(9):644–648.CrossRefPubMedPubMedCentral Croome KP, Chudzinski R, Hanto DW. Increasing time delay from presentation until surgical referral for hepatobiliary malignancies. HPB (Oxford). 2010;12(9):644–648.CrossRefPubMedPubMedCentral
15.
go back to reference Lim C, Bhangui P, Salloum C, Gomez-Gavara C, Lahat E, Luciani A, Compagnon P, Calderaro J, Feray C, Azoulay D. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A hepatocellular carcinoma. J Hepatol. 2017. Lim C, Bhangui P, Salloum C, Gomez-Gavara C, Lahat E, Luciani A, Compagnon P, Calderaro J, Feray C, Azoulay D. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A hepatocellular carcinoma. J Hepatol. 2017.
16.
go back to reference Akce M, Sansgiry S, Temple SL, Davila J, Sada Y. The effect of treatment delay on survival in patients with hepatocellular cancer. J Clin Oncol. 2017;35:15_Suppl.e15645.CrossRef Akce M, Sansgiry S, Temple SL, Davila J, Sada Y. The effect of treatment delay on survival in patients with hepatocellular cancer. J Clin Oncol. 2017;35:15_Suppl.e15645.CrossRef
17.
go back to reference Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, Thoburn K, Gress D, McKellar DP, Shulman LN, Facktor MA, Winchester DP. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–1728.CrossRefPubMed Boffa DJ, Rosen JE, Mallin K, Loomis A, Gay G, Palis B, Thoburn K, Gress D, McKellar DP, Shulman LN, Facktor MA, Winchester DP. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–1728.CrossRefPubMed
18.
go back to reference Chidi AP, Bryce CL, Han K, Dong ZM, Geller DA, Tsung A. Predictors of delay of surgical intervention in patients with hepatocellular carcinoma. J Surg Res. 2014;186:610–611.CrossRef Chidi AP, Bryce CL, Han K, Dong ZM, Geller DA, Tsung A. Predictors of delay of surgical intervention in patients with hepatocellular carcinoma. J Surg Res. 2014;186:610–611.CrossRef
19.
go back to reference Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Stahle E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax. 2004;59(1):45–49.PubMedPubMedCentral Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Stahle E. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax. 2004;59(1):45–49.PubMedPubMedCentral
20.
go back to reference Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol. 2011;6(7):1254–1259.CrossRefPubMed Diaconescu R, Lafond C, Whittom R. Treatment delays in non-small cell lung cancer and their prognostic implications. J Thorac Oncol. 2011;6(7):1254–1259.CrossRefPubMed
21.
go back to reference González-Barcala FJ, García-Prim JM, Álvarez-Dobaño JM, Moldes-Rodriguez M, Garcia-Sanz MT, Pose-Reino A, Valdes-Cuadrado L. Effects of delays on survival in patients with lung cancer. Clin Transl Oncol. 2010(12);12:836.CrossRefPubMed González-Barcala FJ, García-Prim JM, Álvarez-Dobaño JM, Moldes-Rodriguez M, Garcia-Sanz MT, Pose-Reino A, Valdes-Cuadrado L. Effects of delays on survival in patients with lung cancer. Clin Transl Oncol. 2010(12);12:836.CrossRefPubMed
22.
go back to reference Amri R, Bordeianou LG, Sylla P, Berger DL. Treatment delay in surgically-treated colon cancer: does it affect outcomes? Ann Surg Oncol. 2014;21(12):3909–3016.CrossRefPubMed Amri R, Bordeianou LG, Sylla P, Berger DL. Treatment delay in surgically-treated colon cancer: does it affect outcomes? Ann Surg Oncol. 2014;21(12):3909–3016.CrossRefPubMed
23.
go back to reference Crawford SC, Davis JA, Siddiqui NA, de Caestecker L, Gills CR, Hole D, Penney G. The wait time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. BMJ. 2002;325(7357):196.CrossRefPubMedPubMedCentral Crawford SC, Davis JA, Siddiqui NA, de Caestecker L, Gills CR, Hole D, Penney G. The wait time paradox: population based retrospective study of treatment delay and survival of women with endometrial cancer in Scotland. BMJ. 2002;325(7357):196.CrossRefPubMedPubMedCentral
24.
go back to reference Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S, West Midlands Urological Research Group Delay and survival in bladder cancer. BJU Int. 2002;89(9):868–878.CrossRefPubMed Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S, West Midlands Urological Research Group Delay and survival in bladder cancer. BJU Int. 2002;89(9):868–878.CrossRefPubMed
25.
go back to reference Hoehn RS, Hanseman DJ, Jernigan PL, Wima K, Ertel AE, Abbott DE, Shah SA. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford). 2015;17(9):747–752.CrossRefPubMedPubMedCentral Hoehn RS, Hanseman DJ, Jernigan PL, Wima K, Ertel AE, Abbott DE, Shah SA. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford). 2015;17(9):747–752.CrossRefPubMedPubMedCentral
26.
go back to reference Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779–785.CrossRefPubMed Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779–785.CrossRefPubMed
27.
go back to reference Jindal M, Zheng C, Quadri HS, Ihemelandu CU, Hong YK, Smith AK, Dudeja V, Shara NM, Johnson LB, Al-Refaie WB. Why do long-distance travelers have improved pancreatectomy outcomes? J Am Coll Surg. 2017;225(2):216–225.CrossRefPubMedPubMedCentral Jindal M, Zheng C, Quadri HS, Ihemelandu CU, Hong YK, Smith AK, Dudeja V, Shara NM, Johnson LB, Al-Refaie WB. Why do long-distance travelers have improved pancreatectomy outcomes? J Am Coll Surg. 2017;225(2):216–225.CrossRefPubMedPubMedCentral
28.
go back to reference Haddad AQ, Hutchinson R, Wood EL, Miranda G, Gershman B, Messer J, Svatek R, Black PC, Boorjian SA, Shah J, Daneshmand S, Lotan Y. Association of distance to treatment facility with survival and quality outcomes after radical cystectomy: a multi-institutional study. Clin Genitourin Cancer. 2017;15(6):689–695.e2.CrossRefPubMed Haddad AQ, Hutchinson R, Wood EL, Miranda G, Gershman B, Messer J, Svatek R, Black PC, Boorjian SA, Shah J, Daneshmand S, Lotan Y. Association of distance to treatment facility with survival and quality outcomes after radical cystectomy: a multi-institutional study. Clin Genitourin Cancer. 2017;15(6):689–695.e2.CrossRefPubMed
Metadata
Title
Surgical Delay Is Associated with Improved Survival in Hepatocellular Carcinoma: Results of the National Cancer Database
Authors
Kerui Xu
Shinobu Watanabe-Galloway
Fedja A. Rochling
Paraskevi A. Farazi
K. M. Monirul Islam
Hongmei Wang
Jiangtao Luo
Publication date
01-05-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 5/2019
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-018-3925-4

Other articles of this Issue 5/2019

Journal of Gastrointestinal Surgery 5/2019 Go to the issue